---
title: Reduce freezing and improve walking
nct_id: NCT06791902
phase: NA
status: RECRUITING
sponsor: Jocelyne Bloch
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06791902"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06791902"
last_fetched: "2026-05-10T14:02:49.516Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce freezing and improve walking

**Goal (in five words):** Reduce freezing and improve walking

**Official Title:** Study on Preliminary Safety and Efficacy of Adaptive DBS Aligned to Locomotor States to Improve Locomotor Functions in Parkinson's Patients

**Trial ID:** [NCT06791902](https://clinicaltrials.gov/study/NCT06791902)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Jocelyne Bloch
- **Target Enrollment:** 10 participants
- **Start Date:** 2025-01-01
- **Completion Date:** 2027-01-01
- **Conditions:** Parkinson Disease
- **Interventions:** Adaptive DBS
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to improve gait and balance problems in Parkinson's, for example reducing freezing of gait and making walking steadier. The approach uses adaptive deep brain stimulation with the implanted Medtronic Percept system, which reads local field potentials tied to walking and automatically adjusts stimulation in real time so the brain gets different patterns of stimulation during walking versus standing. It works alongside your current DBS device and Parkinson medications, targeting the specific brain rhythms linked to locomotion rather than delivering constant stimulation. The trial is looking for adults 18 and older who already have a full Medtronic Percept suite with bilateral leads, have gait or balance disorders with detectable LFP markers related to locomotion, can consent in French, and meet the study safety criteria.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosed with typical or atypical forms of Parkinson's disease; Suffering from gait or balance disorders;
* Implanted with a full Medtronic Percept suite (neurostimulator Percept PC Model B35200 or Percept RC Model B35300; with bilateral leads (Medtronic Legacy leads (Models 3387 and 3389) or Medtronic SenSightTM Directional Lead (models B33015 and B33005)) and lead extensions (Medtronic extensions (Model 37085 and 37086) or SenSightTM extension (model B34000)), or Medtronic SenSightTM Connector Plug (Model B31061));
* Exhibit modulations in at least one frequency band of the LFP that are related to locomotor states or gait deficits.
* Aged 18 years-old or more;
* Must provide and sign the study's Informed Consent prior to any study-related procedures;
* Able to understand and interact with the study team in French;
* Agree to comply in good faith with all conditions of the recordings, and to attend all required study procedures

Exclusion Criteria:

* Exclusive use of interleaved DBS programs that are incompatible with aDBS;
* High impedances or artefacts in neural signals that obstruct the detection of motor-related biomarkers for adaptive DBS;
* Changes in DBS amplitudes (increase/decrease) not well tolerated;
* Secondary causes of gait problems independent of PD;
* Inability to follow the procedures of the study independently;
* History of major psychiatric disorders or major neurocognitive disorders, as considered by the investigators in according with treating physicians;
* Major changes in PD treatments planned within the course of the study;
* History of drug or alcohol abuse in the past 5 years;
* Pregnancy;
* Participation in another investigational study in the preceding 30 days or during the study
```

## Locations (1)

- CHUV, Lausanne, Canton of Vaud, Switzerland _(46.5160, 6.6328)_
  - Jocelyne Bloch, Prof. MD — (CONTACT) — +41 79 556 2951 — neurorestore.studies@chuv.ch

## Central Contacts

- Jocelyne Bloch, Prof. MD — (CONTACT) — +41 79 556 2951 — jocelyne.bloch@chuv.ch
- Eduardo Martin Moraud, Prof. — (CONTACT) — +41213142455 — Eduardo.Martin-Moraud@chuv.ch

---

*Canonical: https://parkinsonspathways.com/trial/NCT06791902*  
*HTML version: https://parkinsonspathways.com/trial/NCT06791902*  
*Source data: https://clinicaltrials.gov/study/NCT06791902*